PROAD

The PROAD project aims to identify proteomic profiles in blood that can predict cognitive decline in cognitively healthy people with an increased risk of developing Alzheimer's. With this study, in which plasma samples from the Alfa+ cohort will be analyzed, the BBRC team hopes to be able to find new prognostic biomarkers in the preclinical phase of the disease.